Yuan Li-Li, Chen Tian-Yu, Huang Zhi-Qiang
Li-li Yuan, Xingtai Sanli Health Quannan Clinic, Xingtai 054001, Hebei, P. R. China.
Tian-yu Chen, Applied Psychology Major of Shijiazhuang University, Shijiazhuang 050024, Hebei, P. R. China.
Pak J Med Sci. 2023 Jan-Feb;39(1):17-22. doi: 10.12669/pjms.39.1.5679.
To evaluate the effects of paroxetine hydrochloride combined with idebenone on inflammatory factors and antioxidant molecules in the treatment of depression after ischemic stroke.
Randomized controlled trial was adopted on 80 patients with depression after ischemic stroke were randomly divided into two groups, with 40 patients in each group at Xingtai Sanli Health Quannan Clinic from March 17, 2019 to December 20, 2021. Both groups were given basic treatment. On this basis, the control group was treated with paroxetine hydrochloride, while the study group was treated with paroxetine hydrochloride combined with idebenone. The clinical efficacy was evaluated using the Hamilton Rating Scale for Depression (HRSD) before and after treatment. Additionally, the difference in HRSD score after treatment and the improvement in inflammatory factors and antioxidant molecules were compared and analyzed between the two groups.
After treatment, the HRSD score of the study group was significantly improved compared with that of the control group ( 0.00). The effective rate was 82.5% in the study group, which was significantly higher than 62.5% in the control group ( 0.04). After treatment, TNF-a, CRP and IL-6 in the study group were significantly lower than those in the control group (= 0.00). Serum SOD, TAC and CAT levels in the study group were significantly higher than those in the control group after treatment (SOD and TAC, 0.00; CAT, 0.01). The incidence of adverse reactions was 37.5% in the study group and 25% in the control group. Although the incidence of adverse reactions in the study group was higher than that in the control group, the difference was not statistically significant ( 0.23).
Paroxetine hydrochloride combined with idebenone in the treatment of depression after ischemic stroke can significantly improve HRSD score, enhance clinical efficacy, reduce the levels of inflammatory factors, and increase the levels of antioxidant factors, without a significant increase in adverse reactions. Therefore, it is a safe and effective treatment method.
评估盐酸帕罗西汀联合艾地苯醌对缺血性脑卒中后抑郁患者炎症因子及抗氧化分子的影响。
采用随机对照试验,选取2019年3月17日至2021年12月20日在邢台三立健康泉南诊所就诊的80例缺血性脑卒中后抑郁患者,随机分为两组,每组40例。两组均给予基础治疗。在此基础上,对照组给予盐酸帕罗西汀治疗,研究组给予盐酸帕罗西汀联合艾地苯醌治疗。采用汉密尔顿抑郁量表(HRSD)在治疗前后评估临床疗效。此外,比较分析两组治疗后HRSD评分差异以及炎症因子和抗氧化分子的改善情况。
治疗后,研究组HRSD评分较对照组显著改善(P<0.00)。研究组有效率为82.5%,显著高于对照组的62.5%(P=0.04)。治疗后,研究组肿瘤坏死因子-α(TNF-α)、C反应蛋白(CRP)和白细胞介素-6(IL-6)显著低于对照组(P<0.00)。治疗后,研究组血清超氧化物歧化酶(SOD)、总抗氧化能力(TAC)和过氧化氢酶(CAT)水平显著高于对照组(SOD和TAC,P<0.00;CAT,P=0.01)。研究组不良反应发生率为37.5%,对照组为25%。虽然研究组不良反应发生率高于对照组,但差异无统计学意义(P=0.23)。
盐酸帕罗西汀联合艾地苯醌治疗缺血性脑卒中后抑郁可显著改善HRSD评分,提高临床疗效,降低炎症因子水平,增加抗氧化因子水平,且不良反应无显著增加。因此,是一种安全有效的治疗方法。